QCT in ALS Diagnosis, Mechanistic Understanding and Follow-up

Official title

Contribution of the Combined Quadriceps Test (QCT) in the Diagnosis, Mechanistic Understanding and Follow-up of Amyotrophic Lateral Sclerosis

Overview

Multidisciplinary management of amyotrophic lateral sclerosis (ALS) can significantly increase survival but also improve the quality of life of patients. The evaluation of cortical-spinal motor neuron damage is currently based only on the assessment of clinical data. However, the alteration of the central motor pathway and conduction can be identified and quantified by different techniques using motor-evoked potentials (MEP). The combined quadriceps test (QCT) has been developed to assess central and peripheral motor pathway conduction. This test allows to quantify central and peripheral part of a mixed disorder, and to detect physiological hyporeflexia or hyperreflexia which, in the case of suspected ALS, can lead to interpretation problems. The evolution of the QCT parameters during the course of pathology will lead to determine the preponderance of an initial central involvement, but also its extension throughout the pathology. The study of these parameters as well as the clinical course of the disease could reveal a correlation between peripheral and central involvement. This link would provide arguments in favor of pathophysiological hypotheses of disease onset and progression. From a prognostic point of view and depending on the quantification of central and peripheral involvement, the QCT would make it possible to characterize the different ALS phenotypes. This phenotypic characterization would help identify prognostic factors at diagnosis. The investigators propose a cohort study with the exploration of central motor neuron damage by QCT during the course of ALS in order to provide arguments for a better mechanistic understanding and follow-up of this disease with a poor prognosis.

Interventions

• Diagnostic test Quadriceps Combined Test
  The recording of the motor response on the quadriceps is done using self-adhesive surface electrodes on the motor point of the vastus medialis muscles (active electrodes) and on the patella (reference electrode), using a classic electromyography device that allows calculations and measurements of amplitude, duration and speed.

Primary outcome measures

• Parameters from the QCT (Quadriceps Combined Test) [Time frame: At inclusion]
• Parameters from the QCT (Quadriceps Combined Test) [Time frame: Month 6]
• Parameters from the QCT (Quadriceps Combined Test) [Time frame: Month 12]
• Parameters from the QCT (Quadriceps Combined Test) [Time frame: month 18]
• Parameters from the QCT (Quadriceps Combined Test) [Time frame: month 24]
• Parameters from the QCT (Quadriceps Combined Test) [Time frame: At inclusion]
• Parameters from the QCT (Quadriceps Combined Test) [Time frame: month 6]
• Parameters from the QCT (Quadriceps Combined Test) [Time frame: month 12]
• Parameters from the QCT (Quadriceps Combined Test) [Time frame: month 18]
• Parameters from the QCT (Quadriceps Combined Test) [Time frame: month 24]

Secondary outcome measures (12)

• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: At inclusion]
• Clinical and paraclinical likely course data [Time frame: Every 3 months up to 2 years]

Eligibility criteria

Inclusion criteria

• A male or female patient of legal age with suspected ALS (bulbar or spinal) who meets the criteria for "possible", "probable" or "definite" ALS according to the Awaji criteria
• Able to give informed consent to participate in the research
• Enrolled in a Social Security plan

Exclusion criteria

• Pregnant or breastfeeding woman
• Severe progressive pathology other than ALS.
• Comorbidities with another neurological disease altering motor skills.
• Contraindication to trans-cranial magnetic stimulation: epilepsy, pacemaker, intracranial ferromagnetic foreign body (clip, aneurysm, implants)...
• Chronic alcoholism
• Cognitive disorders or major incapacity making it impossible to understand the study and sign an informed consent (fronto-temporal dementia, psychiatric conditions of psychotic type, language disorders)
• Refusal to participate.
• Patients under legal protection (guardianship, curators, safeguard of justice)

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Diagnostic

Study locations

France · 1 center

• CHU de Clermont-Ferrand — Clermont-Ferrand

Identifiers

NCT: NCT06284161 · RBHP 2020 GUY · 2020-A02765-34

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗